After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...
The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.
Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...
Current health news highlights a 10% rise in child TB infections in Europe, a new drug review by European regulators, the ...
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...
(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...
GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...
London open The FTSE 100 is expected to open 28 points higher on Monday, having closed down 0.63% on Friday at 8,646.79.
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment that providers say is critically important to keeping certain patients alive ...